Inter Parfums Inc. (IPAR)
Keep a close eye on IPAR. The company reported strong growth in sales, and said that when it announces its 2014 fourth quarter and full year results in March, IPAR expects to revise the range for its 2015 net income per share guidance upward from its previous guidance of $0.95-$0.98.
For the fourth quarter 2014, IPAR posted consolidated net sales of $125.1 million, an 18.6% increase year over year, and above the above Capital IQ consensus estimate of $120.98 million
IPAR creates, produces, and distributes women's fragrances under different brands in over 100 countries worldwide.
More about Inter Parfums Inc. (IPAR) at www.interparfumsinc.com
**
GW Pharmaceuticals plc (GWPH)
GWPH will report its financial results for the first quarter 2015 on Wednesday February 4, 2015. GWPH will also host a conference call the same day at 8:00 a.m. EST/1:00 p.m. GMT.
GWPH recently said that all aspects of its Epidiolex program to treat orphan syndromes in the field of childhood epilepsy are advancing on time.
GWPH expects to complete pivotal Phase 3 trials by the end of 2015 and, based upon the progress to date, the company expects top-line data from at least one of the pivotal trials in Dravet syndrome (a rare and catastrophic form of intractable epilepsy that begins in infancy), and is working towards top-line data from at least one of the pivotal trials in Lennox-Gastaut Syndrome (a rare and often debilitating form of childhood-onset epilepsy)
According to GWPH, in addition to the formal development programs already underway in both Dravet and Lennox-Gastaut syndromes, data from the expanded access program continues to point to the potential for Epidiolex to treat additional forms of epilepsy and GWPH expects to commence clinical development programs in further potential target indications during 2015
GWPH is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
More about GW Pharmaceuticals plc (GWPH) at www.gwpharm.com
**
Crown Equity Holdings Inc. (OTCPK:CRWE)
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Torrance, CA ( www.torrance.crwe-pr.com ) into the CRWE Network.
Torrance is the eighth largest city in Los Angeles County and competes globally through its myriad of assets: diverse residents, flourishing businesses and safe communities. It is located twenty-five minutes southwest of Los Angeles, California
The City of Torrance had an estimated population in 2013 (U.S. Census Bureau) of 147,478, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company's business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday.
More about Crown Equity Holdings Inc. (OTCPK:CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance ( www.finance.crwe-pr.com ) is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer